Ge Bai

Vice President Kamala Harris announced her proposal for Medicare to cover long-term at-home healthcare for seniors. The fiscal challenge of this proposal is monumental.

The U.S.'s dominance in biotech innovation is critical to our national interests; yet, our government policies are undermining American advantages against China.

Although gender-affirming care is a decision made by the patients in consultation with physicians, it is also funded by employers, other beneficiaries, and taxpayers.

CMS’s debt relief approach, devoid of accountability to taxpayers and riddled with harmful incentives, will worsen medical debt. It’s time to focus on fixing root causes.

The Inflation Reduction Act is unlikely to generate savings for taxpayers, while disrupting the market and creating perverse incentives for the biopharma industry.

HSAs allow patients to benefit from lower prices and better health, reduce risks to medical debt, and offer tax advantages. All Americans should have access to HSAs.

Price transparency is a necessary catalyst to jumpstart the transformation of our healthcare system into a competitive, fair, and patient-oriented one.

For pharmacy benefit managers, our new Congress should focus on removing the flawed rules to improve the game rather than applying Band-Aid solutions to players.

A patriot and leader, Mr. Paul Mango touched the lives of many, leaving behind a tremendous legacy and an inspiring beacon for all fighting for a healthy America.

Health policies have commendable intentions, but the policymaking process is vulnerable to political motivations and industry capture, often leading to unintended consequences.